利沃多巴的微生物代谢作为帕金森病的辅助治疗点
Jimmy B Feix1, Gang Cheng1, Micael Hardy2
1Department of Biophysics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA.
Antioxidants (Basel, Switzerland)
|January 28, 2026
概括
肠道细菌,如Enterococcus faecalis可以分解莱沃多巴,降低帕金森病患者的大脑水平. 新的抗氧化剂可能会抑制这些细菌,提高勒沃多巴的疗效.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种主要的神经退行性疾病.
- 口服乐伏多巴是PD运动缺陷的主要治疗方法.
- 由于副作用和剂量增加,Levodopa的疗效随着疾病的进展而变化和降低.
研究的目的:
- 检查肠道微生物代谢对levodopa生物可用性的影响.
- 为了突出Enterococcus faecalis在莱沃多巴代谢中的作用.
- 探索新的治疗策略,以提高勒沃多巴在PD的疗效.
主要方法:
- 关于肠道细菌和莱沃多巴代谢的最新研究的综述.
- 在Enterococcus faecalis.alis中研究氨酸脱碳酶活性.
- 对抑制E. faecalis生长的线粒体向抗氧化剂的评估.
主要成果:
- 在肠道中,Enterococcus faecalis通过氨酸脱酶代谢莱沃多巴.
- 这种微生物代谢降低了勒沃多巴的生物可用性和大脑多巴胺水平.
- 针对线粒体的抗氧化剂显示出降低E. faecalis及其levodopa代谢的潜力.
结论:
- 肠道微生物群显著影响莱沃多巴在帕金森病中的疗效.
- 通过Enterococcus faecalis介导的乐伏多巴代谢是一个关键因素.
- 调节肠道微生物群,而不是抗生素,为PD提供了一个有希望的治疗途径.
相关概念视频
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...